Planned withdrawal of dexamethasone after pomalidomide low-dose dexamethasone induction for lenalidomide-refractory multiple myeloma (ALLG MM14)

Anna Kalff; Tiffany Khong; Malarmathy Ramachandran; P. Joy Ho; Peter Mollee; James D’Rozario; Kerry Taylor; Jane Estell; Sam Norton; Roslyn Kemp; Andrew J. Mitchell; John Reynolds; Nola Kennedy; Hang Quach; Andrew Spencer

doi:10.3324/haematol.2021.278655

Planned withdrawal of dexamethasone after pomalidomide low-dose dexamethasone induction for lenalidomide-refractory multiple myeloma (ALLG MM14)

Anna Kalff, Tiffany Khong, Malarmathy Ramachandran, P. Joy Ho, Peter Mollee, James D’Rozario, Kerry Taylor, Jane Estell, Sam Norton, Roslyn Kemp, Andrew J. Mitchell, John Reynolds, Nola Kennedy, Hang Quach, Andrew Spencer

Research output: Contribution to journal › Letter › Research › peer-review

1 Citation (Scopus)

Original language	English
Pages (from-to)	321-325
Number of pages	5
Journal	Haematologica
Volume	107
Issue number	1
DOIs	https://doi.org/10.3324/haematol.2021.278655
Publication status	Published - Jan 2022

Access to Document

10.3324/haematol.2021.278655

Cite this

Kalff, A., Khong, T., Ramachandran, M., Joy Ho, P., Mollee, P., D’Rozario, J., Taylor, K., Estell, J., Norton, S., Kemp, R., Mitchell, A. J., Reynolds, J., Kennedy, N., Quach, H., & Spencer, A. (2022). Planned withdrawal of dexamethasone after pomalidomide low-dose dexamethasone induction for lenalidomide-refractory multiple myeloma (ALLG MM14). Haematologica, 107(1), 321-325. https://doi.org/10.3324/haematol.2021.278655

@article{9ff689ff2475404f95e298cc83c0b65d,

title = "Planned withdrawal of dexamethasone after pomalidomide low-dose dexamethasone induction for lenalidomide-refractory multiple myeloma (ALLG MM14)",

author = "Anna Kalff and Tiffany Khong and Malarmathy Ramachandran and {Joy Ho}, P. and Peter Mollee and James D{\textquoteright}Rozario and Kerry Taylor and Jane Estell and Sam Norton and Roslyn Kemp and Mitchell, {Andrew J.} and John Reynolds and Nola Kennedy and Hang Quach and Andrew Spencer",

note = "Funding Information: Acknowledgements: We would like to thank all the patients and their families for participating in the study and our colleagues at participating hospitals who contributed to the study. Funding: this work was supported by grants from Celgene Corporation and The Merrin Foundation. Funding Information: Disclosures: AK received honoraria from Amgen, Celgene/BMS, Pfizer, Janssen and Roche. CSL received honoraria from Sandoz. AS consults for Takeda, Secura Bio, Servier, Clegene, Amgen, Abbvie, Specialized Therapeutics Australia; received honoraria from Servier, Celgene, Amgen, Abbvie, Specialized Therapeutics Australia, is part of the Speakers Bureau of Takeka, Jansen and Celgene; received research funding from Celgene and Amgen. HQ consults for Amgen, Celgene, Sanofi Genzyme, and Jansen; received research funding from Amgen, Celgene and Sanofi Genzyme; is part of the scientific steering committee of Amgen, Karyopharm and GSK. JDR sits on the advisory board of Celgene and Abbvie; received honoraria from Celgene and Abbvie. JE sits on the advisory board of Janssen and Celgene. JR received honoraria from Novartis Australia, is employed by Alfred Health; acts as a biostatistician for trials funded by the Australian government and Abbvie, Amgen, Celgene, GSK, Janssen-Cilag, Merck, Novartis, Takeda, but sponsored by Alfred Health.; consults for the Australasian Leukemia & Lymphoma Group (ALLG); owns equity of Novartis AG. PM sits on the advisory board of Janssen, BMS/Celgene, Amgen, Takeka, Pfizer and Caelum (no personal fees received from any of them); received research funding from Janssen. All other authors have no conflicts of interest to disclose.",

year = "2022",

month = jan,

doi = "10.3324/haematol.2021.278655",

language = "English",

volume = "107",

pages = "321--325",

journal = "Haematologica",

issn = "0390-6078",

publisher = "Fondazione Ferrata Storti",

number = "1",

}

Kalff, A, Khong, T, Ramachandran, M, Joy Ho, P, Mollee, P, D’Rozario, J, Taylor, K, Estell, J, Norton, S, Kemp, R, Mitchell, AJ, Reynolds, J, Kennedy, N, Quach, H & Spencer, A 2022, 'Planned withdrawal of dexamethasone after pomalidomide low-dose dexamethasone induction for lenalidomide-refractory multiple myeloma (ALLG MM14)', Haematologica, vol. 107, no. 1, pp. 321-325. https://doi.org/10.3324/haematol.2021.278655

TY - JOUR

T1 - Planned withdrawal of dexamethasone after pomalidomide low-dose dexamethasone induction for lenalidomide-refractory multiple myeloma (ALLG MM14)

AU - Kalff, Anna

AU - Khong, Tiffany

AU - Ramachandran, Malarmathy

AU - Joy Ho, P.

AU - Mollee, Peter

AU - D’Rozario, James

AU - Taylor, Kerry

AU - Estell, Jane

AU - Norton, Sam

AU - Kemp, Roslyn

AU - Mitchell, Andrew J.

AU - Reynolds, John

AU - Kennedy, Nola

AU - Quach, Hang

AU - Spencer, Andrew

N1 - Funding Information: Acknowledgements: We would like to thank all the patients and their families for participating in the study and our colleagues at participating hospitals who contributed to the study. Funding: this work was supported by grants from Celgene Corporation and The Merrin Foundation. Funding Information: Disclosures: AK received honoraria from Amgen, Celgene/BMS, Pfizer, Janssen and Roche. CSL received honoraria from Sandoz. AS consults for Takeda, Secura Bio, Servier, Clegene, Amgen, Abbvie, Specialized Therapeutics Australia; received honoraria from Servier, Celgene, Amgen, Abbvie, Specialized Therapeutics Australia, is part of the Speakers Bureau of Takeka, Jansen and Celgene; received research funding from Celgene and Amgen. HQ consults for Amgen, Celgene, Sanofi Genzyme, and Jansen; received research funding from Amgen, Celgene and Sanofi Genzyme; is part of the scientific steering committee of Amgen, Karyopharm and GSK. JDR sits on the advisory board of Celgene and Abbvie; received honoraria from Celgene and Abbvie. JE sits on the advisory board of Janssen and Celgene. JR received honoraria from Novartis Australia, is employed by Alfred Health; acts as a biostatistician for trials funded by the Australian government and Abbvie, Amgen, Celgene, GSK, Janssen-Cilag, Merck, Novartis, Takeda, but sponsored by Alfred Health.; consults for the Australasian Leukemia & Lymphoma Group (ALLG); owns equity of Novartis AG. PM sits on the advisory board of Janssen, BMS/Celgene, Amgen, Takeka, Pfizer and Caelum (no personal fees received from any of them); received research funding from Janssen. All other authors have no conflicts of interest to disclose.

PY - 2022/1

Y1 - 2022/1

UR - http://www.scopus.com/inward/record.url?scp=85122322914&partnerID=8YFLogxK

U2 - 10.3324/haematol.2021.278655

DO - 10.3324/haematol.2021.278655

M3 - Letter

C2 - 34587718

AN - SCOPUS:85122322914

SN - 0390-6078

VL - 107

SP - 321

EP - 325

JO - Haematologica

JF - Haematologica

IS - 1

ER -

Planned withdrawal of dexamethasone after pomalidomide low-dose dexamethasone induction for lenalidomide-refractory multiple myeloma (ALLG MM14)

Access to Document

Other files and links

Cite this